Last reviewed · How we verify
Small intestinal release peppermint oil
Peppermint oil works by relaxing the muscles in the small intestine, reducing spasms and cramping.
Peppermint oil works by relaxing the muscles in the small intestine, reducing spasms and cramping. Used for Irritable bowel syndrome (IBS) symptoms, including abdominal pain and cramping.
At a glance
| Generic name | Small intestinal release peppermint oil |
|---|---|
| Also known as | Tempocol, Peppermint oil, Menthae piperitae aetheroleum, Tempocol®, A03AX15 |
| Sponsor | Maastricht University Medical Center |
| Drug class | Gastrointestinal motility agent |
| Modality | Small molecule |
| Therapeutic area | Gastrointestinal |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of peppermint oil in the small intestine is not fully understood, but it is thought to work by blocking calcium channels and reducing the release of acetylcholine, a neurotransmitter that stimulates muscle contractions.
Approved indications
- Irritable bowel syndrome (IBS) symptoms, including abdominal pain and cramping
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- Peppermint Oil for the Treatment of Irritable Bowel Syndrome or Functional Abdominal Pain in Children: the MINT Study (PHASE3)
- Enteric-Coated Peppermint Oil Versus Standard Antispasmodic in SLC6A4 (5-HTTLPR) Carriers With Irritable Bowel Syndrome. (NA)
- Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®), a Pharmacokinetic Study (PHASE2)
- Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: